The values and corporate philosophy represented by CardioGenics Holdings Inc are centered around innovation, excellence, and commitment to patient care. The company aims to revolutionize the diagnostic testing market with its proprietary immunoassay technology platform. Emphasizing evidence-based medicine, CardioGenics focuses on developing advanced diagnostic tools to improve cardiovascular health outcomes. By integrating cutting-edge technology, scientific expertise, and a patient-centric approach, the company strives to provide accurate, timely, and cost-effective testing solutions. CardioGenics also values transparency, collaboration, and trust to build sustainable partnerships within the healthcare industry.

CardioGenics Holdings Inc is primarily present in the United States and Canada.

CardioGenics Holdings Inc has achieved several significant milestones throughout its journey. The company successfully developed its proprietary technology, the QL Care Analyzer, which enables point-of-care diagnosis for patients with cardiac conditions. Additionally, CardioGenics Holdings Inc obtained regulatory approvals for its products, allowing for commercialization in key markets. The company has also established strategic partnerships, expanding its reach and enhancing its market presence. Furthermore, CardioGenics Holdings Inc has made substantial progress in research and development, continuously innovating to provide advanced cardiac diagnostic solutions. These achievements demonstrate CardioGenics Holdings Inc as a leading player in the cardiovascular diagnostics industry, committed to improving patient care with cutting-edge technologies.

CardioGenics Holdings Inc. is a renowned healthcare company specializing in the development and commercialization of cutting-edge medical diagnostic products. Established in [year], CardioGenics has been dedicated to revolutionizing the field of cardiovascular diagnostics. The company focuses on advanced immunoassay-based diagnostic testing solutions that offer unparalleled accuracy and efficiency. With a strong commitment to research and development, CardioGenics has successfully introduced innovative products that measure various biomarkers, aiding in the diagnosis and monitoring of heart-related conditions. By combining technology, scientific expertise, and a profound understanding of cardiovascular diseases, CardioGenics has emerged as a leader in the industry, continually striving to improve patient outcomes worldwide.

The main competitors of CardioGenics Holdings Inc in the market include companies like Abbott Laboratories, Medtronic PLC, Siemens Healthineers AG, and Roche Holding AG.

CardioGenics Holdings Inc is primarily active in the medical device industry.

The business model of CardioGenics Holdings Inc focuses on developing and commercializing innovative medical products for the diagnosis and management of cardiovascular diseases. The company specializes in the development of proprietary immunoassay technologies, which are used to detect the presence of cardiac markers in blood samples. By leveraging these advanced technologies, CardioGenics aims to provide accurate and efficient diagnostic solutions for healthcare professionals. The company's commitment to innovation and expertise in the cardiovascular field contributes to its goal of improving patient outcomes and driving growth in the medical diagnostics industry.

KGV за CardioGenics Holdings в момента не може да бъде изчислено.

KUV за CardioGenics Holdings в момента не може да бъде изчислено.

AlleAktien качественият резултат за CardioGenics Holdings е 4/10.

Приходите не могат да бъдат изчислени в момента за CardioGenics Holdings.

Печалбата за CardioGenics Holdings в момента не може да бъде изчислена.

CardioGenics Holdings Inc is a biotechnology company specializing in the development of diagnostic instruments for heart diseases. The company's business model includes various divisions, including research and development, production, marketing, and distribution. The company produces a range of in-vitro diagnostic instruments and equipment to detect heart diseases. These products are specifically designed to improve the precision and accuracy of diagnoses, thereby facilitating clinical decision-making. This includes the QL Care Analyzer product range, which allows measuring heart markers using finger blood. These products are also user-friendly and provide quick results. Another part of CardioGenics' business model is the novel technology behind their products. The company has developed its own version of the "Magnetic Bead Technology" process, which allows for rapid and accurate detection and identification of specific antigens or antibodies. This technology is a unique and innovative method of in-vitro diagnostics, giving CardioGenics a competitive advantage in the market. CardioGenics also utilizes partnerships and collaborations to expand their portfolio and sell their products in a wider range of markets. Collaboration and franchise agreements with companies such as Shanghai Biotech, Inc. and Sapphire Biotech, Inc. help increase their reach in international markets. Distribution and marketing are also essential for CardioGenics. The company utilizes both traditional and digital strategies to promote their offerings. Presence at trade shows and conferences, advertising in professional magazines, and online promotion on social media platforms help increase awareness and interest in their offerings. They also have an online shop that makes their products digitally accessible to customers and retailers. CardioGenics' focus on heart diseases makes their business model highly targeted and enables high precision in their products. This type of specialization is an important factor for success in a competitive market. Additionally, CardioGenics offers a range of products tailored to meet the needs of customers and retailers. Overall, CardioGenics' business model is based on a focused approach that emphasizes innovative technology, precision, collaborations, and marketing strategies. The company aims to maintain a broad range of products, enter new markets, and expand its global presence.

CardioGenics Holdings разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за CardioGenics Holdings в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на CardioGenics Holdings е US14160X2036.

WKN на CardioGenics Holdings е A1C048.

Тикерът на CardioGenics Holdings е CGNH.

През последните 12 месеца CardioGenics Holdings изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква CardioGenics Holdings да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на CardioGenics Holdings в момента е .

CardioGenics Holdings изплаща дивидент на тримесечие. Той се разпределя в месеците .

CardioGenics Holdings платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

CardioGenics Holdings се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от CardioGenics Holdings на 21.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 21.09.2024 г..

Последното дивидентно плащане беше извършено на 21.09.2024 г..

През година 2023 CardioGenics Holdings изплати 0 USD под формата на дивиденти.

Дивидентите от CardioGenics Holdings се изплащат в USD.